Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men

Christine M. Barnett, Carrie Nielson, Jackilen (Jackie) Shannon, June M. Chan, James M. Shikany, Douglas C. Bauer, Andrew R. Hoffman, Elizabeth Barrett-Connor, Eric Orwoll, Tomasz (Tom) Beer

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Objective: Multiple studies have shown clear evidence of vitamin D's anti-tumor effects on prostate cancer cells in laboratory experiments, but the evidence has not been consistent in humans. We sought to examine the association between vitamin D and prostate cancer risk in a cohort of older men. Methods: We conducted a prospective case-cohort study nested within the multicenter Osteoporotic Fractures in Men (MrOS) study. Baseline serum 25-OH vitamin D was measured in a randomly selected sub-cohort of 1,433 men ≥ 65 years old without a history of prostate cancer and from all participants with an incident diagnosis of prostate cancer (n = 297). Cox proportional hazards models were used to evaluate the associations between quartiles of total 25-OH vitamin D and incident prostate cancer, as well as Gleason score. Results: In comparison with the lowest quartile of 25-OH vitamin D, the hazard ratio for the highest quartile of 25-OH vitamin D was 1.22 (CI 0.50-1.72, p = 0.25), no trend across quartiles (p = 0.94) or association with Gleason score was observed. Adjustment for covariates did not alter the results. Conclusions: In this prospective cohort of older men, we found no association between serum 25-OH vitamin D levels and subsequent risk of prostate cancer.

Original languageEnglish (US)
Pages (from-to)1297-1303
Number of pages7
JournalCancer Causes and Control
Volume21
Issue number8
DOIs
StatePublished - Aug 2010

Fingerprint

Vitamin D
Prostatic Neoplasms
Serum
Neoplasm Grading
Osteoporotic Fractures
Proportional Hazards Models
Vitamins
Cohort Studies
Neoplasms

Keywords

  • Prostate cancer
  • Vitamin D

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. / Barnett, Christine M.; Nielson, Carrie; Shannon, Jackilen (Jackie); Chan, June M.; Shikany, James M.; Bauer, Douglas C.; Hoffman, Andrew R.; Barrett-Connor, Elizabeth; Orwoll, Eric; Beer, Tomasz (Tom).

In: Cancer Causes and Control, Vol. 21, No. 8, 08.2010, p. 1297-1303.

Research output: Contribution to journalArticle

Barnett, CM, Nielson, C, Shannon, JJ, Chan, JM, Shikany, JM, Bauer, DC, Hoffman, AR, Barrett-Connor, E, Orwoll, E & Beer, TT 2010, 'Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men', Cancer Causes and Control, vol. 21, no. 8, pp. 1297-1303. https://doi.org/10.1007/s10552-010-9557-y
Barnett, Christine M. ; Nielson, Carrie ; Shannon, Jackilen (Jackie) ; Chan, June M. ; Shikany, James M. ; Bauer, Douglas C. ; Hoffman, Andrew R. ; Barrett-Connor, Elizabeth ; Orwoll, Eric ; Beer, Tomasz (Tom). / Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. In: Cancer Causes and Control. 2010 ; Vol. 21, No. 8. pp. 1297-1303.
@article{46fce66fd33241efb4dc6f21dda7dd6a,
title = "Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men",
abstract = "Objective: Multiple studies have shown clear evidence of vitamin D's anti-tumor effects on prostate cancer cells in laboratory experiments, but the evidence has not been consistent in humans. We sought to examine the association between vitamin D and prostate cancer risk in a cohort of older men. Methods: We conducted a prospective case-cohort study nested within the multicenter Osteoporotic Fractures in Men (MrOS) study. Baseline serum 25-OH vitamin D was measured in a randomly selected sub-cohort of 1,433 men ≥ 65 years old without a history of prostate cancer and from all participants with an incident diagnosis of prostate cancer (n = 297). Cox proportional hazards models were used to evaluate the associations between quartiles of total 25-OH vitamin D and incident prostate cancer, as well as Gleason score. Results: In comparison with the lowest quartile of 25-OH vitamin D, the hazard ratio for the highest quartile of 25-OH vitamin D was 1.22 (CI 0.50-1.72, p = 0.25), no trend across quartiles (p = 0.94) or association with Gleason score was observed. Adjustment for covariates did not alter the results. Conclusions: In this prospective cohort of older men, we found no association between serum 25-OH vitamin D levels and subsequent risk of prostate cancer.",
keywords = "Prostate cancer, Vitamin D",
author = "Barnett, {Christine M.} and Carrie Nielson and Shannon, {Jackilen (Jackie)} and Chan, {June M.} and Shikany, {James M.} and Bauer, {Douglas C.} and Hoffman, {Andrew R.} and Elizabeth Barrett-Connor and Eric Orwoll and Beer, {Tomasz (Tom)}",
year = "2010",
month = "8",
doi = "10.1007/s10552-010-9557-y",
language = "English (US)",
volume = "21",
pages = "1297--1303",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "8",

}

TY - JOUR

T1 - Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men

AU - Barnett, Christine M.

AU - Nielson, Carrie

AU - Shannon, Jackilen (Jackie)

AU - Chan, June M.

AU - Shikany, James M.

AU - Bauer, Douglas C.

AU - Hoffman, Andrew R.

AU - Barrett-Connor, Elizabeth

AU - Orwoll, Eric

AU - Beer, Tomasz (Tom)

PY - 2010/8

Y1 - 2010/8

N2 - Objective: Multiple studies have shown clear evidence of vitamin D's anti-tumor effects on prostate cancer cells in laboratory experiments, but the evidence has not been consistent in humans. We sought to examine the association between vitamin D and prostate cancer risk in a cohort of older men. Methods: We conducted a prospective case-cohort study nested within the multicenter Osteoporotic Fractures in Men (MrOS) study. Baseline serum 25-OH vitamin D was measured in a randomly selected sub-cohort of 1,433 men ≥ 65 years old without a history of prostate cancer and from all participants with an incident diagnosis of prostate cancer (n = 297). Cox proportional hazards models were used to evaluate the associations between quartiles of total 25-OH vitamin D and incident prostate cancer, as well as Gleason score. Results: In comparison with the lowest quartile of 25-OH vitamin D, the hazard ratio for the highest quartile of 25-OH vitamin D was 1.22 (CI 0.50-1.72, p = 0.25), no trend across quartiles (p = 0.94) or association with Gleason score was observed. Adjustment for covariates did not alter the results. Conclusions: In this prospective cohort of older men, we found no association between serum 25-OH vitamin D levels and subsequent risk of prostate cancer.

AB - Objective: Multiple studies have shown clear evidence of vitamin D's anti-tumor effects on prostate cancer cells in laboratory experiments, but the evidence has not been consistent in humans. We sought to examine the association between vitamin D and prostate cancer risk in a cohort of older men. Methods: We conducted a prospective case-cohort study nested within the multicenter Osteoporotic Fractures in Men (MrOS) study. Baseline serum 25-OH vitamin D was measured in a randomly selected sub-cohort of 1,433 men ≥ 65 years old without a history of prostate cancer and from all participants with an incident diagnosis of prostate cancer (n = 297). Cox proportional hazards models were used to evaluate the associations between quartiles of total 25-OH vitamin D and incident prostate cancer, as well as Gleason score. Results: In comparison with the lowest quartile of 25-OH vitamin D, the hazard ratio for the highest quartile of 25-OH vitamin D was 1.22 (CI 0.50-1.72, p = 0.25), no trend across quartiles (p = 0.94) or association with Gleason score was observed. Adjustment for covariates did not alter the results. Conclusions: In this prospective cohort of older men, we found no association between serum 25-OH vitamin D levels and subsequent risk of prostate cancer.

KW - Prostate cancer

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=77955715436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955715436&partnerID=8YFLogxK

U2 - 10.1007/s10552-010-9557-y

DO - 10.1007/s10552-010-9557-y

M3 - Article

C2 - 20383574

AN - SCOPUS:77955715436

VL - 21

SP - 1297

EP - 1303

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 8

ER -